NCT01123811已完成2 期
An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer
Johannes Gutenberg University Mainz10 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2006年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
- 试验地点
- 10
- 主要终点
- objective response rate
研究概览
简要总结
Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in gastric cancer , the present clinical study to evaluate the overall response rate, the time to progression and the overall survival of the combined treatment of cetuximab and irinotecan and 5-FU in patients with esophagogastric cancer is urgently needed.
详细描述
Cetuximab will be analysed with biological markers
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent before the start of specific protocol procedures;
- •Histologically proven gastric adenocarcinoma including adenocarcinoma of the esophagogastric junction or Barrett carcinoma (adenocarcinoma of lower oesophagus);
- •Measurable metastatic disease according to the RECIST criteria. If locally recurrent disease, it must be associated with at least one measurable lymph node (> 20 mm by CT scan or > 10 mm with spiral CT);
- •Age: 18-75 years;
- •ECOG Performance Status 0-2
- •Life expectancy > 12 weeks;
- •Adequate hematological, hepatic and renal functions: ANC
- •≥ 1.5 × 109/L, platelets ≥ 100 × 109/L; hemoglobin ≥ 10g/dl; creatinine ≤ 2 x UNL; total bilirubin ≤ 3 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 3 × UNL; in case of liver metastases: total bilirubin ≤ 5 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 5 × UNL;
- •At least 4 weeks from surgery;
- •Recovery from side effects of any prior therapy;
- •Able to comply with scheduled assessments and with management of toxicity.
- •If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing.
排除标准
- •Other tumor type than adenocarcinoma (e.g., leiomyosarcoma, lymphoma) or a second cancer except in patients with squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix which has been effectively treated. Patients curatively treated and disease free for at least 5 years will be discussed with the sponsor before inclusion;
- •Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol;
- •Any prior palliative chemotherapy, adjuvant (and/or neoadjuvant) chemotherapy or radiotherapy ;
- •Concurrent treatment with any other anti-cancer therapy;
- •Patients with known brain or leptomeningeal metastasis;
- •Hypercalcemia not controlled by bisphosphonates;
- •Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (> hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis;
- •Other serious illness or medical conditions:
- •Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry; congestive heart failure NYHA grade 3 and 4;
- •Current history of chronic diarrhea;
- •History of significant neurologic or psychiatric disorders including dementia or seizures;
- •Active uncontrolled infection;
- •Active disseminated intravascular coagulation;
- •Other serious underlying medical conditions which could impair the ability of the patient to participate in the study;
- •Known deficit in DPD
- •Contraindications to the use of atropine;
- •Concomitant or within a 4-week period administration of any other experimental drug under investigation;
- •Pregnant or lactating women;
- •Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR pathway targeting therapy;
- •Known allergic/hypersensitivity reaction to any of the components of the treatment;
- •Known drug abuse/alcohol abuse.
研究组 & 干预措施
Cetuximab IF
Experimental
Treatment with combination of Cetuximab and Irinotecan 5-FU
干预措施: Cetuximab IF (Drug)
结局指标
主要结局
objective response rate
时间窗: 1 month
次要结局
- Progression-free survival(1 month)
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer - CetIriPatients with esofagus- and gastric cancerMedDRA version: 9.1Level: LLTClassification code 10017758Term: Gastric cancerEUCTR2008-006168-12-DKOdense University Hospital55
已完成
2 期
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01387880Herlev Hospital100
已完成
2 期
Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011362Osaka City University20
招募中
2 期
Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix studycolorectal cancerJPRN-UMIN000003483Kitasato University East Hospital Department of gastroenterological surgery, Department of gastroenterology38
已完成
2 期
Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancerMetastatic colorectal cancerJPRN-UMIN000019893The Cancer Institute Hospital, Japanese Foundation for Cancer Research35